Product Description
Amoxicillin is used to treat certain infections caused by bacteria, such as pneumonia; bronchitis (infection of the airway tubes leading to the lungs); and infections of the ears, nose, throat, urinary tract, and skin. It is also used in combination with other medications to eliminate H. pylori, a bacteria that causes ulcers. Amoxicillin is in a class of medications called penicillin-like antibiotics. It works by stopping the growth of bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a685001.html)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company Founding Year: 2000
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Benin, Canada, China, Colombia, Croatia, Czech Republic, Estonia, Finland, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Kenya, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Serbia, Slovenia, Spain, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 11
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: COVID-19|Fractures, Open|Influenza, Human|Pneumonia|Respiratory Tract Infections|Urinary Tract Infections
Phase 2: Buruli Ulcer|Diverticulitis
Phase 1: Abscess|Bronchitis|Bronchitis, Chronic|Cellulitis|Community-Acquired Infections|Cystitis|Escherichia coli Infections|Haemophilus Infections|Helicobacter Infections|Osteomyelitis|Other|Otitis Media|Pharyngitis|Pneumonia, Bacterial|Proteus Infections|Pyelonephritis|Short Bowel Syndrome|Sinusitis|Soft Tissue Infections|Tonsillitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20253270 |
CTR20253270 | P1 |
Completed |
Pharyngitis|Bronchitis|Influenza, Human|Escherichia coli Infections|Soft Tissue Infections|Tonsillitis|Sinusitis|Haemophilus Infections|Respiratory Tract Infections|Pneumonia|Otitis Media|Proteus Infections|Helicobacter Infections |
2025-10-14 |
2025-11-16 |
||
NCT05584683 |
LP-001 | P1 |
Completed |
Other |
2024-12-16 |
12% |
2025-02-06 |
Primary Endpoints |
NCT05302531 |
GRAAL | P1 |
Recruiting |
Short Bowel Syndrome |
2024-12-01 |
50% |
2024-11-27 |
Primary Endpoints|Treatments |
CTR20241408 |
CTR20241408 | P1 |
Completed |
Pyelonephritis|Soft Tissue Infections|Cellulitis|Bronchitis, Chronic|Sinusitis|Urinary Tract Infections|Cystitis|Osteomyelitis|Respiratory Tract Infections|Otitis Media|Pneumonia, Bacterial|Abscess|Community-Acquired Infections |
2024-07-09 |
2025-08-24 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2023-506224-87-00 |
DIREBIOT | P2 |
Recruiting |
Diverticulitis |
2025-12-31 |
2025-05-02 |
Treatments |
|
2023-508442-18-00 |
DURATIOM | P3 |
Not yet recruiting |
Fractures, Open |
2027-12-31 |
2025-05-02 |
Treatments |
|
NCT02735707 |
REMAP-CAP | P3 |
Recruiting |
COVID-19|Pneumonia|Influenza, Human |
2026-02-01 |
2024-11-27 |
||
NCT05169554 |
BLMs4BU | P2 |
Recruiting |
Buruli Ulcer |
2026-05-31 |
12% |
2024-05-17 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
CTR20230643 |
CTR20230643 | P1 |
Completed |
Helicobacter Infections |
2023-04-28 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT04041791 |
SEARCH | P3 |
Completed |
Pneumonia |
2024-04-05 |
2024-05-23 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
|
CTR20131000 |
CTR20131000 | P3 |
Recruiting |
Respiratory Tract Infections|Urinary Tract Infections |
None |
2025-04-29 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/12/2026 |
News Article |
Beta-Lactam Allergy Delabeling Safe for Pregnant Patients |
|
02/05/2026 |
News Article |
Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026 |
|
02/04/2026 |
News Article |
Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program |
|
01/07/2026 |
News Article |
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants |